Profile Picture
Rewards
  • All
  • Images
  • Videos
  • Maps
  • News
  • Shopping
  • More
    • Flights
    • Travel
    • Hotels
  • Top stories
  • Sports
  • U.S.
  • Local
  • World
  • Science
  • Technology
  • Entertainment
  • Politics
  • Business

Trending on Bing

N. Korea to expel US soldier
Hired men to kidnap son?
‘I’m so tired’
Edward James Olmos Day
Accused of charity theft
Binance to exit Russia
Masked teens loot stores
‘I haven’t had the stress’
Import ban on 3 CN firms
Burna Boy announces tour
Expecting first child together
5 cops hurt in knife attack
Sanders' son hospitalized
Saints signing QB Luton
$2B to build battery plant
$230M to settle opioid cases
Coach punched teen player?
Las Vegas hospitality strike
Daniel Ekuale on IR
Rabid otter bites Fla. man
Seeks up to $90B valuation
Files for divorce dismissal
Google turns 25
Brewers clinch NL Central
Johnson intrigued by Knicks
Mass. $1B tax relief deal
2026 bid for Calif. governor
Radiologists outperform AI
RU air strikes hit UKR port
'Wasn't funny enough for me'
Votes to advance funding bill
Returns after a year in space
  • Any time
    • Past hour
    • Past 24 hours
    • Past 7 days
    • Past 30 days
  • Best match
    • Most recent
158,000 results
1hon MSN
Health Headlines: FDA approves Alzheimer treatment
CLEVELAND, Ohio (Ivanhoe Newswire) – More than six million Americans are living with Alzheimer’s disease, it slowly steals ...
朝日新聞社8d
Alzheimer’s drug Leqembi has full FDA approval
Alzheimer’s drug Leqembi has full FDA approval THE ASSOCIATED PRESS July 7, 2023 at 07:30 JST Share Tweet list Print This image provided by Eisai in January 2023 shows vials and packaging for ...
The Bismarck Tribune
19h
Experimental treatment pushed by ALS patients gets day before FDA, but agency unconvinced it works
The Food and Drug Administration is considering a much-debated new treatment for Lou Gehrig’s disease, a deadly neurological ...
Seeking Alpha18d
Vigil Neuroscience study for Alzheimer's drug to proceed with FDA restrictions
Vigil Neuroscience (NASDAQ:VIGL) said the FDA is allowing a Phase 1 clinical trial for its Alzheimer’s drug candidate VG-3927 to proceed with a partial clinical hold related to the maximum drug ...
Medical Xpress25d
Unlocking how the new Alzheimer's drug lecanemab works
Approved by the FDA earlier this year, the Alzheimer's therapy lecanemab is an antibody that reduces the buildup in the brain of a sticky peptide called amyloid-beta (Aβ), which is thought to be ...
1don MSN
After US approval, Japan OKs Leqembi, its first Alzheimer’s drug, developed by Eisai and Biogen
Japan’s health ministry has approved Leqembi, a drug for Alzheimer’s decease that was jointly developed by Japanese and U.S. pharmaceutical companies.
Forbes16d
What To Know About The Alzheimer’s Drug Leqembi
Commissions we earn from partner links on this page do not affect our opinions or evaluations. Our editorial content is based on thorough research and guidance from the Forbes Health Advisory Board.
Washington Examiner26d
FDA needs to let go of its risk-averse regulatory model
The FDA also gave full approval to a drug called Leqembi, which slowed Alzheimer’s patients’ functional and cognitive decline by 27% over 18 months, according to trial data.
Science Daily2d
Alzheimer's News
Sep. 22, 2023 — Research reveals new non-coding genetic variants associated with Alzheimer's disease functioning in microglia -- brain cells already implicated in the progression of this often ...
pharmaphorum3d
Celgene’s multiple myeloma orphan drug gets FDA approval
Celgene’s multiple myeloma treatment has been approved by the US FDA. Pomalyst has been approved to treat patients with this form of blood cancer whose disease progressed after being treated ...
The Financial Times23d
Vivek Ramaswamy’s FDA ‘corruption’ claims disavowed by Roivant
We’ll send you a myFT Daily Digest email rounding up the latest Vivek Ramaswamy news every morning. US biotech company Roivant Sciences has moved to distance itself from its founder, Vivek ...
Science Daily2d
Alzheimer's Research News
Sep. 18, 2023 — Is it possible that a single biomarker can detect all types of diseases related to dopamine deficiency in the brain? Yes, that's what a research group is discovering. 'We have ...

Some results have been hidden because they may be inaccessible to you

Show inaccessible results
© 2023 Microsoft
  • Privacy and Cookies
  • Legal
  • Advertise
  • About our ads
  • Help
  • Feedback
  • Your Privacy Choices